12月11日 - ** 药物开发商RezoluteRZLT.O股价盘前下跌91%至1.04美元
** Rezolute公司称， (link)，其治疗一种罕见疾病的实验性药物未能在后期试验中达到主要目标。
** RZLT公司的药物ersodetug正在先天性高胰岛素血症患者中进行试验，这是一种罕见疾病，患者胰腺中的β细胞会分泌过多的胰岛素。
** Rezolute 计划与美国 FDA 会面，讨论进一步措施
** 截至 上一交易日收盘，该公司股价已上涨一倍多
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.